Koyfin Home > Directory > Health Care > Acceleron Pharma > Long-term Debt / Equity

Acceleron Pharma Long-term Debt / Equity Chart (XLRN)

Acceleron Pharma annual/quarterly Long-term Debt / Equity from 2012 to 2020.
  • Acceleron Pharma Long-term Debt / Equity for the quarter ending June 06, 2020 was $4m a -17.01% decrease of -1m year over year
  • Acceleron Pharma Long-term Debt / Equity for the last 12 months ending June 06, 2020 was $4m a -17.01% decrease of -1m year over year
  • Acceleron Pharma Annual Long-term Debt / Equity for 2019 was $4m a 1,855.83% increase of 83m from 2018
  • Acceleron Pharma Annual Long-term Debt / Equity for 2012 was $-79m
Other Ratios Metrics:
  • Acceleron Pharma Total Debt / Capital for the quarter ending December 12, 2013 was $23m a -6,253.89% decrease of -1,413m year over year
  • Acceleron Pharma Other Liabilities for the quarter ending December 12, 2018 was $4m a 14.46% increase of 1m year over year
  • Acceleron Pharma Total Debt / Equity for the quarter ending December 12, 2013 was $29m
View Chart On Koyfin

Quarterly XLRN Long-term Debt / Equity Data

06/2020$4m
03/2020$4m
12/2019$4m
09/2019$5m
06/2019$5m
03/2019$5m
09/2013$15m
06/2013$-244m
03/2013$-78m
12/2012$-79m

Annual XLRN Long-term Debt / Equity Data

2019$4m
2012$-79m